FGC BOLSA - FGC FINANCIAL MARKETS INFO

Daily Stocks to Watch Thu Jul 1 09:02 2010   Stocks To Watch Jul 1, 2010 ReneSola Reveals Q2 Unaudited Revenue Above Estimates - Stocks to Watch ReneSola Ltd. (SOL) revealed it expects net revenues for the second quarter of 2010 to be in the range of US$245 million to US$255 million, exceeding the company's previous guidance range of US$230 million to US$250 million and representing an increase of approximately 21.0% to 25.8% from US$206.6 million in Q1 2010. Full Article Jul 1, 2010 Introducing RTT Growth & Value Stocks The Growth & Value Stocks service is designed with a disciplined approach of extensive fundamental analysis to cater swing traders and investors. The service identifies growth stocks that are generally overlooked and value stocks that are usually undervalued by the market. The growth and value stocks we select have significantly outperformed the broader market indices. Full Article

Daily Stocks to Watch Tue Jun 15 09:02 2010   Stocks To Watch Jun 15, 2010 Fertile and Blooming… Increasing consumer concerns about food safety and shrinking acreages of arable land have helped this China-based organic fertilizer maker grow revenue and profit multi-fold in the last four years. Full Article Jun 15, 2010 ArtiCure Gets FDA Clearance for Heart Device - Stocks to Watch Monday afer the bell, AtriCure, Inc. (ATRC) said it received U.S. FDA's clearance for its AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion system. The AtriClip system prevents blood from entering and forming clots in the left atrial appendage, a hollow sac-like structure attached to the heart's left upper chamber, during atrial fibrillation, commonly known as irregular heart beats. The company said initial launch in the U.S. Full Article Jun 15, 2010 Introducing RTT Growth & Value Stocks The Growth & Value Stocks service is designed with a disciplined

Daily Stocks to Watch Thu Jun 3 09:02 2010   Stocks To Watch Jun 3, 2010 In the chips… This U.S. based semiconductor equipment company basks in the recovery glow lighting the sector and has nearly tripled revenues in the last four quarters. Full Article Jun 3, 2010 Novartis' Cancer Drug Afinitor Meets Goal in Late-stage Pancreatic Tumor Trial - Stocks to Watch Early morning on Thursday, pharma major Novartis AG (NVS) revealed that its cancer drug Afinitor met the primary endpoint in a Phase III study on patients with advanced pancreatic neuroendocrine tumors. Novartis said the study results indicated that Afinitor, generically known as everolimus, when combined with supportive care, significantly extended progression-free survival, or absence of tumor growth, in patients with advanced pancreatic neuroendocrine tumors, or pancreatic NET. In the European Union, everolimus is approved under the trade name Afinitor for treating patients with advanced re